|
Gerald L. Andriole, M.D., has been appointed chief of the Division of Urology at the School of Medicine, succeeding William J. Catalona, M.D. Department of Surgery Chair Timothy J. Eberlein, M.D., announced the appointment, effective Jan. 1.
Andriole has been a faculty member in the Department of Surgery's urology division since 1985. He is an internationally known urologic oncologist, specializing in prostate cancer and a noncancerous condition called prostatic hyperplasia.
"Washington University is at the forefront of urologic research and patient care," Andriole said. "I am proud to carry on the tradition of excellence, committed to the patients of St. Louis and around the country who come here for treatment and am equally dedicated to providing outstanding educational opportunities for our medical students and residents.
"I am indebted to Bill Catalona for bringing me to St. Louis and will always be grateful for the opportunities he and the university have provided me."
As director of the Prostate Study Center at Barnes-Jewish West County Hospital since 1990, Andriole has performed more than 30 trials of new medications and devices for the treatment of urological diseases. His funding from the National Institutes of Health to study cancer screening and benign prostatic enlargement totals more than $14 million.
He leads the St. Louis portion of a National Cancer Institute study known as the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. This large-scale study will determine whether widespread use of certain cancer-screening tests can save lives.
Andriole has published more than 100 papers on the detection and treatment of prostate cancer and other genital and urinary problems. He also was instrumental in demonstrating the safety of a procedure called hemodilution, which permits radical prostatectomy patients to avoid blood transfusions by donating several units of their own blood minutes before surgery. The blood is then returned at the end of surgery.
Andriole is editor-in-chief of the Yearbook of Urology and is on the editorial advisory boards of Surgical Rounds, Infections in Urology, The Prostate Journal and Urology International. He is a reviewer for numerous other journals, including the Journal of the American Medical Association, Journal of Urology, Cancer and Annals of Surgical Oncology.
He holds administrative and leadership positions on several national trials, including the Prostate Cancer Chemoprevention Trial and the Prostate Intervention Versus Observation Trial. In addition, he is chairman of the Genitourinary Committee of the American College of Surgeons Oncology Group and serves on the advisory boards of several pharmaceutical companies with an interest in prostatic and other urologic diseases.
Through an accelerated medical program, he received both bachelor's and medical degrees within a five-year period from Pennsylvania State University and Jefferson Medical College, respectively. Following a surgical residency at the University of Rochester and a urology residency at Harvard, he went to the National Cancer Institute to serve as a urologic oncologist. Two years later, he was recruited to Washington University as an assistant professor of urologic surgery and chief of urology for the St. Louis Veterans Affairs Medical Center.
Catalona and Andriole have collaborated over the years on several projects.
